503b glp-1 FDA says that the shortage is over Key Aspects of 503B Compounding

Some users report a mild warm or flushing sensation shortly after injection

To view or add a comment, sign in Ahead of the July 2026 Pharmacy Compounding Advisory Committee meeting, the FDA has released its scientific briefing documents

CagriSema is Novo Nordisk's fixed-dose combination of cagrilintide (a long-acting amylin analog) and semaglutide (a GLP-1 agonist) in a single once-weekly injection

Patient Education and Prevention Our care doesnt stop after treatment

However, if the swollen area grows larger than 2 inches in diameter or doesnt improve after two days, its time to reach out to your doctor

Serious side effects are rare but will be closely monitored